Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

By means of indirect immunofluorescence a number of primary lung cancer patient sera and control sera were tested for anti-tumor antibody activity on living tumor cells as a substrate. Antibodies against surface antigens were the most frequently detected in autologous system (in 65%) on cells derived from fresh surgical material of lung cancer. They were also found in 50% of cases using tumor cells from primary short-term culture. When established cell line of lung cancer was used (E-14) in allogeneic system, the antibodies were detected in only 22% of examined lung cancer sera. Absorption of positive sera with homogenates of normal tissues did not abolish their specific activity. Positive reactions were confined to squamous cell type of bronchogenic carcinoma.
 ...
PMID:Anti-tumor antibodies in lung cancer patients. Immunofluorescence study using various indicator cells. 39 79

Since 1963 to 1975 one hundred and eighty eight patients were subjected to surgery with preoperative irradiation, using a betatron of 25 M. e. v. Irradiation was carried on during 2--3 weeks from 2 or 3 fields daily. A total focal dose ranged within the limits from 2500 to 4500 rad. Radical operations were performed in 159 patients, the mortality being 6.7%. The survival over 3 years--in 69.1%, over 5 years--in 57.3%. Postoperative irradiation using a betatron of 25 M. e. v. is found to contribute to an improvement of general condition in lung cancer patients and to render a positive effect on clinical and roentgenological signs of the disease. A comparative morphological study of diagnostic biopsy specimens and lung preparations, removed following irradiation, indicates various degree of cancer pathomorphosis up to tumor disappearrance and development of radiation sclerosis.
 ...
PMID:[Combined treatment of lung cancer]. 40 62

Charts of 437 patients having plasma carcinoembryonic antigen determinations during the period January 1, 1976 through April 30, 1976 were reviewed to determine whether CEA results led to clinical decisions altering management patterns. Data analysis disclosed that CEA test results did not result in any change in management in 167 patients with non-neoplastic disease. Most had single determinations. In 270 patients with neoplastic disease, CEA results led to changes in management in one patient with lung cancer and two patients with colon cancer, which may have altered prognosis. In a fourth patient, CEA results led to discovery of unresectable pancreatic cancer at laparotomy. Cost benefit analysis indicated a CEA test cost of $5,047.50 per patient benefitted in 299 patients eligible for analysis. We conclude that maximal benefit to the patient results from serial CEA test use in follow-up of colon cancer patients after curative therapy.
 ...
PMID:The use and abuse of CEA test in clinical practice. 41 1

Immunosuppression in 45 patients with lung cancer was studied by examining delayed cutaneous hypersensitivity reactions to DNCB and by analyzing the effect of the patient's serum on the proliferative response of normal donor lymphocytes. Both diminution of DNCB reactivity and inhibition of the proliferative response of normal donor lymphocytes to mitogens were associated with the stage of the disease and the presence of unresected tumor. Suppressive sera were associated with poor prognosis. The suppressive effects of patients' sera on lymphocytes from a normal donor suggest that the immunosuppression seen in lung cancer may be mediated by serum factors. The significant association of clinically evident tumor with this serum-mediated immunosuppression further suggests that the tumor itself could account for the appearance of these factors in the host. The clinical implications of these findings may be useful for designing new clinical trials.
 ...
PMID:Serum-mediated immunosuppression in lung cancer. 42 31

A system using the fluorescence bronchoscope has been designed for localization of small, early bronchogenic carcinoma by the fluorescence of previously injected hematoporphyrin derivative. The system included a 200W mercury vapor lamp and primary filter, flexible fiberoptic bronchoscope with special violet-transmitting light conductor, secondary filter, and image intensifier tube. Tests indicated the system could detect a tumor only 100 micron thick at the expected concentration of hematoporphyrin derivative: 1 microgram/gm at 48 to 96 hours following intravenous injection at a dosage of 2.5 mg/kg. Examination of resected specimens (six of lung, one of esophagus) showed positive fluorescence in all cases, with fluorescence visible beyond the region visible under conventional white light examination. Fluorescence bronchoscopy has been performed on four patients thus far. Positive fluorescence was observed in all three cases where the tumor had been known to occur. Positive fluorescence was also observed in the patient with sputum positive for lung cancer, but negative x-ray film findings. However, additional examinations are required to demonstrate the smallest lesion that can be detected in vivo.
 ...
PMID:Fluorescence bronchoscopy for detection of lung cancer. 44 68

Administration of oil-attached Nocardia rubra cell-wall skeleton (N. rubra-CWS) was evaluated for the effect of the induction of lung cancers in ACI/N rats. Lung cancers were induced by 15 weekly intratracheal instillations of 3 mg benzo[a]-pyrene with 3 mg ferric oxide. After the 10th instillation of the carcinogen, rats received seven subcutaneous injections of 100 microgram of N. rubra-CWS at 2-week intervals. In the observation period of 56 weeks, the cumulative incidence of lung cancer was 71.4% in the control group and 48.0% in the N. rubra-CWS treated group. The latent period of tumor induction was prolonged in the group treated with N. rubra-CWS.
 ...
PMID:Effect of Nocardia rubra cell-wall skeleton on the induction of lung cancer in ACI/N rats. 44 76

Cytotoxicity of peripheral blood lymphocytes against allogeneic target cells of bronchogenic carcinoma was examined by a microcytotoxicity test before, during, and after radiotherapy in primary lung cancer patients. Before the treatment, cytotoxicity was depressed only slightly in patients in stage III and strikingly in those in stage IV, as compared to the values in patients at earlier stages of lung cancer such as stages I AND II. Local irradiation scarcely affected cytotoxicity at stages II and III, but augmented remarkably at stage IV. The number of peripheral blood lymphocytes decreased profoundly during and after radiotherapy in all cases of stages II, III, and IV. Although radiotherapy exhibited various effects on the cytotoxic activity of lymphocytes and the number of peripheral blood lymphocytes, only the cytotoxic activity at the end of radiotherapy correlated well with the reduction in tumor size.
 ...
PMID:Effect of radiotherapy on lymphocyte cytotoxicity against allogeneic lung cancer cells in patients with bronchogenic carcinoma. 44 78

Carcinoma of the lung has been steadily increasing since World War II, and the family physician can now expect to see a greater incidence of the disease in women and persons under age 50 years. The clinical manifestations of carcinoma of the lung are described, based on a 14-year experience at the University of Michigan. Diagnostic procedures are outlined. The preferred treatment for carcinoma of the lung is pulmonary resection, combined, in appropriate situations, with mediastinal lymph node irradiation. Survival is dependent to some degree on the tumor cell type as well as the extent of metastasis. A new immunotherapeutic adjunct to resection and irradiation is being developed. Five to ten-year survivors of resections for lung cancer and normal persons serve as lymphocyte donors. Transfer factor is extracted from these lymphocytes and injected into selected patients who have recently had resections for lung cancer. It is too soon to evaluate the results of this experiment, but it is hoped that immunotherapy using transfer factor will be of help to patients with carcinoma of the lung.
 ...
PMID:Clinical presentation and management of patients with carcinoma of the lung: a 14-year experience. 44 96

Serum lysozyme has been demonstrated to be an indicator for macrophage activity in the tumor-bearing host. Therefore, we investigated lysozyme levels in the sera of 336 untreated tumor patients (121 malignant melanoma, 61 lung cancers, 70 cervical cancers, 49 breast cancers and 35 benign breast tumors, and 36 healthy controls). Patients with malignant melanoma and lung cancer had significantly higher lysozyme levels than the healthy controls. Within the clinical stages in melanoma, there was a decrease of lysozyme in stages II and III in comparison to stage I, but still above that of the control values. Patients with benign breast tumors had normal levels, whereas in breast cancer patients of stages I and II there was a significant reduction in the lysozyme levels. In stages III and IV no differences to the control group could be detected. In patients with cervical cancer (FIGO II and III) serum lysozyme levels were found to be within the normal range. From this study it can not be concluded that serum lysozyme reflects the immunological reactivity of the tumor bearer. Nevertheless, the reduced levels in stages I and II of breast cancer might point to an immunological defect.
 ...
PMID:Serum lysozyme levels in patients with solid tumors. 45 Mar 87

Sixty patients with lung cancer, 48 with extensive disease and 12 with regional disease, were treated with cyclophosphamide and methotrexate on a schedule based on cellular kinetics concepts. Initial therapy was with cyclophosphamide (1.1 g/m2 iv) followed by methotrexate (20 mg/m2 orally twice weekly) beginning 9 days later when the tumor was considered to be most susceptible to an S-phase-specific drug. The overall objective response rate was 62% (25% complete responses and 37% partial responses) with an estimated median survival time (MST) of 46 weeks. Seventeen of 19 patients with small cell carcinoma (89%) responded (ten complete responses and seven partial responses). The MST was 62 weeks. The last nine patients entered in the study with small cell carcinoma had an MST of 71 weeks, reflecting additional responses to subsequent treatment. The objective response rate of large cell carcinoma (nine of 16 patients) and adenocarcinoma (ten of 18 patients) was 56%. The MST of patients with the former cell type was longer (57 weeks) than that of patients with the latter cell type (34 weeks). One of seven patients with epidermoid carcinoma responded. The MSTs of patients with a complete response and those with regional disease were 70 and 63 weeks respectively. Patients with a performance status of 0 or 1 survived longer (MST, 56 weeks) than those with a performance status of 2 or 3 (MST, 29 weeks). The mean dose of cyclophosphamide per course was 1.275 g/m2 and the mean nadir leukocyte count per patient was 2890/mm3. The incidence per course of leukocytes less than 1000/mm3 or platelets less than 50,000/mm was less than 3%. Mucositis was common. This schedule provides excellent maintenance therapy without undue toxicity. These survival time distributions compare favorably with those of previous reports, particularly for patients with small cell or large cell carcinoma, regional disease, or complete responses.
 ...
PMID:Cytokinetic chemotherapy design for the treatment of advanced lung cancer. 45 13


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>